FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2741232330> ?p ?o ?g. }

• W2741232330 endingPage "82660" @default.
• W2741232330 startingPage "82643" @default.
• W2741232330 abstract "// Hengwei Fan 1, * , Wanwan Yi 2, * , Chenxing Wang 1 and Jisheng Wang 1 1 Department of Hepatobiliary Surgery, The 2nd Affiliated Hospital & Yuying Children’s Hospital, Wenzhou Medical University, Zhejiang 325027, China 2 Department of Nuclear Medicine, Shanghai Tenth People’s Hospital, Tongji University, Shanghai 200072, China * These authors have contributed equally to this work Correspondence to: Jisheng Wang, email: 18321775325@163.com Keywords: EMMPRIN, prognosis, clinicopathological significance, cancer, meta-analysis Received: November 10, 2016      Accepted: June 20, 2017      Published: July 31, 2017 ABSTRACT Extracellular matrix metalloproteinase inducer (EMMPRIN) has been reported to be associated with tumor formation and invasion in many studies. However, the clinicopathological significance and prognosis of EMMPRIN in cancer patients remains inconclusive. Therefore, we conducted a meta-analysis to assess the predictive potential of EMMPRIN in various cancers. By searching Pubmed, Cochrane library database and web of science comprehensively, 39studies with 5739 cases were included in our meta-analysis. The results indicated that EMMPRIN overexpression was significantly associated with poor outcome of cancers (HR=2.46, 95% CI: 2.21-2.75, P<0.0001). In addition, a significant relation was found between EMMPRIN overexpression and clinicopathological features, such as tumor stage (T3+T4/ T1+T2, OR=1.87, 95% CI:1.64-2.12, P<0.0001), tumor differentiation (poor/ well+ moderate, OR=1.09, 95% CI:1.60-2.23, P<0.0001), clinical stage (III+IV /I +II, OR=1.96, 95% CI:1.69-2.27, P<0.0001) and nodal metastasis (positive/negative, OR=2.37, 95% CI:1.93-2.90, P<0.0001). However, the expression of EMMRIN was not significantly associated with tumor stage in cervical cancer (OR=1.35, 95%CI: 0.73-2.48, P=0.33). In conclusion, EMMPRIN overxepression is significantly associated with clinicopathological characteristics and prognosis of cancers. Thus, EMMPRIN may be regarded as a promising bio-marker in predicting the clinical outcome of patients in cancers and could be used as the therapeutic target during clinical practices." @default.
• W2741232330 created "2017-08-08" @default.
• W2741232330 creator A5019091721 @default.
• W2741232330 creator A5028053683 @default.
• W2741232330 creator A5035414806 @default.
• W2741232330 creator A5069787815 @default.
• W2741232330 date "2017-07-31" @default.
• W2741232330 modified "2023-09-23" @default.
• W2741232330 title "The clinicopathological significance and prognostic value of EMMPRIN overexpression in cancers: evidence from 39 cohort studies" @default.
• W2741232330 cites W17855875 @default.
• W2741232330 cites W1802829593 @default.
• W2741232330 cites W188363728 @default.
• W2741232330 cites W1888322781 @default.
• W2741232330 cites W1966592996 @default.
• W2741232330 cites W1973421725 @default.
• W2741232330 cites W1978577165 @default.
• W2741232330 cites W1980640760 @default.
• W2741232330 cites W1985922338 @default.
• W2741232330 cites W1987684813 @default.
• W2741232330 cites W1990150777 @default.
• W2741232330 cites W1990886776 @default.
• W2741232330 cites W2003647237 @default.
• W2741232330 cites W2005083104 @default.
• W2741232330 cites W2011716233 @default.
• W2741232330 cites W2017823697 @default.
• W2741232330 cites W2020765834 @default.
• W2741232330 cites W2021196979 @default.
• W2741232330 cites W2023736297 @default.
• W2741232330 cites W2024627467 @default.
• W2741232330 cites W2028333923 @default.
• W2741232330 cites W2029815823 @default.
• W2741232330 cites W2031919949 @default.
• W2741232330 cites W2042168169 @default.
• W2741232330 cites W2042714647 @default.
• W2741232330 cites W2044366730 @default.
• W2741232330 cites W2047735724 @default.
• W2741232330 cites W2050224943 @default.
• W2741232330 cites W2053250998 @default.
• W2741232330 cites W2053471840 @default.
• W2741232330 cites W2054869536 @default.
• W2741232330 cites W2057119326 @default.
• W2741232330 cites W2058993987 @default.
• W2741232330 cites W2062522653 @default.
• W2741232330 cites W2064013437 @default.
• W2741232330 cites W2066624242 @default.
• W2741232330 cites W2067345725 @default.
• W2741232330 cites W2069279091 @default.
• W2741232330 cites W2070389231 @default.
• W2741232330 cites W2072997351 @default.
• W2741232330 cites W2077161651 @default.
• W2741232330 cites W2079741978 @default.
• W2741232330 cites W2081314682 @default.
• W2741232330 cites W2082319264 @default.
• W2741232330 cites W2090364322 @default.
• W2741232330 cites W2102207579 @default.
• W2741232330 cites W2106882655 @default.
• W2741232330 cites W2115264886 @default.
• W2741232330 cites W2123519880 @default.
• W2741232330 cites W2130437991 @default.
• W2741232330 cites W2135964373 @default.
• W2741232330 cites W2141310469 @default.
• W2741232330 cites W2144176257 @default.
• W2741232330 cites W2145435404 @default.
• W2741232330 cites W2153566920 @default.
• W2741232330 cites W2154382883 @default.
• W2741232330 cites W2154807688 @default.
• W2741232330 cites W2164687062 @default.
• W2741232330 cites W2164756915 @default.
• W2741232330 cites W2195485492 @default.
• W2741232330 cites W2235523093 @default.
• W2741232330 cites W2357329626 @default.
• W2741232330 cites W2402984302 @default.
• W2741232330 cites W3141109100 @default.
• W2741232330 cites W3143245705 @default.
• W2741232330 cites W4362124050 @default.
• W2741232330 cites W4379370243 @default.
• W2741232330 cites W9040215 @default.
• W2741232330 doi "https://doi.org/10.18632/oncotarget.19740" @default.
• W2741232330 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5669917" @default.
• W2741232330 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29137291" @default.
• W2741232330 hasPublicationYear "2017" @default.
• W2741232330 type Work @default.
• W2741232330 sameAs 2741232330 @default.
• W2741232330 citedByCount "6" @default.
• W2741232330 countsByYear W27412323302019 @default.
• W2741232330 countsByYear W27412323302021 @default.
• W2741232330 countsByYear W27412323302022 @default.
• W2741232330 countsByYear W27412323302023 @default.
• W2741232330 crossrefType "journal-article" @default.
• W2741232330 hasAuthorship W2741232330A5019091721 @default.
• W2741232330 hasAuthorship W2741232330A5028053683 @default.
• W2741232330 hasAuthorship W2741232330A5035414806 @default.
• W2741232330 hasAuthorship W2741232330A5069787815 @default.
• W2741232330 hasBestOaLocation W27412323301 @default.
• W2741232330 hasConcept C121608353 @default.
• W2741232330 hasConcept C126322002 @default.
• W2741232330 hasConcept C143998085 @default.
• W2741232330 hasConcept C146357865 @default.

• next